F M Germaschewski1, C J Matheny2, J Larkin2, F Liu2, L R Thomas3, J S Saunders2, K Sully3, C Whittall4, Y Boyle5, G Peters5, N M Graham4. 1. GlaxoSmithKline Biopharmaceutical Research & Development, Stevenage, Herts, UK. Electronic address: fiona.m.germaschewski@gsk.com. 2. GlaxoSmithKline Research & Development, King of Prussia, PA, USA. 3. GlaxoSmithKline Biopharmaceutical Research & Development, Stevenage, Herts, UK. 4. Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Oswestry, Shropshire, UK. 5. GlaxoSmithKline Clinical Unit, Addenbrookes, Cambridge, UK.
Abstract
OBJECTIVE: To characterise ARGS neoepitope concentrations in various matrices from patients with knee osteoarthritis (OA) and assess performance of an immunoassay to facilitate clinical development of therapeutics affecting the A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS-5) pathway. DESIGN: Matched sera, urine, and synovial fluid (SF) (surgical subjects only) were collected from healthy subjects, subjects with knee OA (non-surgical OA), and OA subjects undergoing total knee replacement (OA-TKR; n = 20 per group). Diurnal and inter-day variation was evaluated in the non-surgical OA group over 3 separate visits. Serum and urine samples were collected on two visits for the OA-TKR group with SF taken only at the time of surgery. ARGS neoepitope was quantitated using an optimized immunoassay. RESULTS: Serum ARGS neoepitope concentrations were elevated in OA-TKR subjects compared to non-surgical OA subjects (P = 0.005) and healthy subjects (P = 0.0002). Creatinine corrected urinary ARGS neoepitope concentrations were more variable, but were also elevated in the OA-TKR subjects compared to healthy subjects (P = 0.008). No significant diurnal effect or inter-day variance was observed in serum or urine. Serum ARGS neoepitope concentrations correlated with age (P = 0.0252) but not with total number of joints with OA involvement. SF ARGS neoepitope concentrations correlated with Western Ontario and MacMaster OA Index (WOMAC) stiffness score (P = 0.04) whereas a weaker, non-significant trend towards positive correlation with combined WOMAC score and the number of concurrent joints was observed. CONCLUSIONS: This study utilized a sensitive and robust assay to evaluate ARGS neoepitope concentrations in various matrices in OA patients and healthy volunteers. ARGS neoepitope appears promising as a prognostic/stratification marker to facilitate patient selection and as an early pharmacodynamic marker for OA therapeutic trials.
OBJECTIVE: To characterise ARGS neoepitope concentrations in various matrices from patients with knee osteoarthritis (OA) and assess performance of an immunoassay to facilitate clinical development of therapeutics affecting the A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS-5) pathway. DESIGN: Matched sera, urine, and synovial fluid (SF) (surgical subjects only) were collected from healthy subjects, subjects with knee OA (non-surgical OA), and OA subjects undergoing total knee replacement (OA-TKR; n = 20 per group). Diurnal and inter-day variation was evaluated in the non-surgical OA group over 3 separate visits. Serum and urine samples were collected on two visits for the OA-TKR group with SF taken only at the time of surgery. ARGS neoepitope was quantitated using an optimized immunoassay. RESULTS: Serum ARGS neoepitope concentrations were elevated in OA-TKR subjects compared to non-surgical OA subjects (P = 0.005) and healthy subjects (P = 0.0002). Creatinine corrected urinary ARGS neoepitope concentrations were more variable, but were also elevated in the OA-TKR subjects compared to healthy subjects (P = 0.008). No significant diurnal effect or inter-day variance was observed in serum or urine. Serum ARGS neoepitope concentrations correlated with age (P = 0.0252) but not with total number of joints with OA involvement. SF ARGS neoepitope concentrations correlated with Western Ontario and MacMaster OA Index (WOMAC) stiffness score (P = 0.04) whereas a weaker, non-significant trend towards positive correlation with combined WOMAC score and the number of concurrent joints was observed. CONCLUSIONS: This study utilized a sensitive and robust assay to evaluate ARGS neoepitope concentrations in various matrices in OA patients and healthy volunteers. ARGS neoepitope appears promising as a prognostic/stratification marker to facilitate patient selection and as an early pharmacodynamic marker for OA therapeutic trials.
Authors: J Larkin; T A Lohr; L Elefante; J Shearin; R Matico; J-L Su; Y Xue; F Liu; C Genell; R E Miller; P B Tran; A-M Malfait; C C Maier; C J Matheny Journal: Osteoarthritis Cartilage Date: 2015-03-20 Impact factor: 6.576
Authors: Ellen van der Aar; Henri Deckx; Sonia Dupont; Ann Fieuw; Stephane Delage; Staffan Larsson; André Struglics; L Stefan Lohmander; Agnes Lalande; Emilie Leroux; David Amantini; Paul Passier Journal: Clin Pharmacol Drug Dev Date: 2021-12-02
Authors: S Roberts; H Evans; K Wright; L van Niekerk; B Caterson; J B Richardson; K H S Kumar; J H Kuiper Journal: Osteoarthritis Cartilage Date: 2015-05-21 Impact factor: 6.576
Authors: Yunyun Luo; Yi He; Ditte Reker; Natasja Stæhr Gudmann; Kim Henriksen; Ole Simonsen; Christoph Ladel; Martin Michaelis; Ali Mobasheri; Morten Karsdal; Anne-Christine Bay-Jensen Journal: Int J Mol Sci Date: 2018-11-06 Impact factor: 5.923